People: Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

18 Apr 2019
Change (% chg)

$-0.87 (-1.94%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Aurentz, Vincent 

Mr. Vincent Aurentz is an Executive Vice President and Chief Business Officer of the Company. Previously, Mr. Aurentz served as the Chief Business Officer of Epirus Biopharmaceuticals, Inc. from November 2015 to July 2016. Prior to Epirus, Mr. Aurentz served as President of HemoShear Therapeutics, LLC from July 2013 to November 2015, where he oversaw the scientific research and business development efforts including collaborations with global organizations such as Pfizer Inc., Eli Lilly, Janssen R&D and Children’s National Health System. Prior to HemoShear, Mr. Aurentz served as Executive-in-Residence at Catenion GmbH from July 2012 to December 2014, and served as Executive Vice President of Quintiles Transnational from October 2010 to April 2012. Prior to that, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono S.A.) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments, Co-founder and Managing Director of a venture capital and advisory business, and started his career at Andersen Consulting (now Accenture). In July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Aurentz received a B.S. in mathematics from Villanova University.

Basic Compensation

Total Annual Compensation, USD 785,905
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 826,746
Fiscal Year Total, USD 1,612,650

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tina Nova


Amit Munshi


Kevin Lind


Steven Spector


Vincent Aurentz


Preston Klassen

As Of  31 Dec 2017